Richter Gedeon buys Dita group for 14.5M euros

22 December 2006

Hungarian drugmaker Richter Gedeon says that Armedica Trading SLR, in which it holds a 98.11% stake, has completed the acquisition of Romanian drug wholesaler, the Dita Group for a consideration of 14.5 million euros ($19.1 million). The firm explained that the Dita group comprises three companies with bases in Bucharest and Craiova in Romania, as well as Kolozsvar in Hungary.

Richter said that the purchase, which is still subject to authorization from the country's competition authorities, will increase its share of the Romanian wholesale drug market by 3% to 4.5%, which includes the contribution made by the previously-acquired Sibofarm SA.

Richter also announced that it has completed the purchase of the rights of operation for about 60 pharmacies in the region, via retail companies and pharmacy licenses acquired previously. The company explained that the deal, which was carried out via a second subsidiary, Richter Gedeon Farmacia SA, was designed to develop its position in Romania. Financial terms of the acquisition were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight